Skip to main content

Table 2 Influence of depression on RA disease activity, pain and fatigue over 12 months

From: Baseline predictors of remission, pain and fatigue in rheumatoid arthritis: the TITRATE trial

   Crude Adjusteda
β (95%CI) p value β (95%CI) p value
Average scores (0, 6 and 12 months)
DAS28-ESR None Reference   Reference  
Moderate 0.13 (−0.10, 0.36) 0.278 0.07 (−0.19, 0.33) 0.595
Severe 0.24 (0.02, 0.46) 0.030 0.03 (−0.29, 0.36) 0.838
Pain None Reference   Reference  
Moderate 5.72 (0.66, 10.77) 0.027 0.88 (−4.49, 6.25) 0.749
Severe 11.88 (7.06, 16.71) <0.001 −0.88 (−7.57, 5.81) 0.796
Fatigue None Reference   Reference  
Moderate 13.12 (7.33, 18.91) <0.001 10.13 (4.20, 16.07) 0.001
Severe 24.76 (19.56, 29.96) <0.001 17.07 (9.76, 24.37) <0.001
12-month outcomes
   Crude
Odds ratio (95%CI)
p value Adjusteda
Odds ratio (95%CI)
p value
Remission DAS28-ESR (<2.6) None Reference   Reference  
Moderate 1.28 (0.62, 2.65) 0.500 1.43 (0.64, 3.19) 0.377
Severe 0.78 (0.37, 1.62) 0.498 0.77 (0.35, 1.73) 0.535
Change in pain (≥10 units) None Reference   Reference  
Moderate 0.89 (0.46, 1.72) 0.726 0.66 (0.31, 1.37) 0.264
Severe 1.17 (0.64, 2.13) 0.608 1.19 (0.62, 2.29) 0.597
Change in fatigue (≥10 units) None Reference   Reference  
Moderate 1.61 (0.84, 3.11) 0.152 1.59 (0.76, 3.34) 0.219
Severe 1.25 (0.68, 2.28) 0.469 1.40 (0.72, 2.73) 0.321
  1. aAdjustment for age, gender, ethnicity, disease duration, NHS region and trial arm; Depression: none n=125; moderate n=76; severe n=94